Literature DB >> 26932915

Inadequacy of Headache Management After Subarachnoid Hemorrhage.

Elizabeth K Glisic1, Linda Gardiner2, Linda Josti2, Elizabeth Dermanelian2, Sandra Ridel2, John Dziodzio2, Barbara McCrum2, Ben Enos2, Patricia Lerwick2, Gilles L Fraser2, Paul Muscat2, Richard R Riker2, Robert Ecker2, Jeffrey Florman2, David B Seder2.   

Abstract

BACKGROUND: Headache profoundly affects management of spontaneous subarachnoid hemorrhage but is poorly characterized.
OBJECTIVE: To characterize headache after spontaneous subarachnoid hemorrhage.
METHODS: Medical records of patients with Hunt and Hess grades I-III subarachnoid hemorrhage admitted from 2011 to 2013 were reviewed. Demographics, clinical and radiographic features, medications, and pain scores were recorded through day 14 after hemorrhage. Headache pain was characterized on the basis of a numeric rating scale and analgesic use. Severe headache was defined as 2 or more days with maximum pain scores of 8 or greater or need for 3 or more different analgesics for 2 or more days. Univariate and multivariable models were used to analyze factors associated with severe headache.
RESULTS: Of the 77 patients in the sample, 57% were women; median age was 57 years. Severe headache (73% overall) was associated nonlinearly with Hunt and Hess grade: grade I, 58%; grade II, 88%; and grade III, 56% (P = .01), and with Hijdra score: score 0-10, 56%; score 11-20, 86%; score 21-30, 76% (P = .03). By univariate analysis, patients with low Hijdra scores were less likely to have severe headache (27% vs 57%; P = .02). In a multivariable model, younger age and higher Hijdra score tended to be associated with severe headache.
CONCLUSIONS: Headache after spontaneous subarachnoid hemorrhage was often severe, necessitating multiple opioid and nonopioid analgesics. Many patients reported persistent headache and inadequate pain control. ©2016 American Association of Critical-Care Nurses.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26932915     DOI: 10.4037/ajcc2016486

Source DB:  PubMed          Journal:  Am J Crit Care        ISSN: 1062-3264            Impact factor:   2.228


  6 in total

1.  Acute Headache Management for Patients with Subarachnoid Hemorrhage: An International Survey of Health Care Providers.

Authors:  Carolina B Maciel; Brooke Barlow; Brandon Lucke-Wold; Arravintha Gobinathan; Zaid Abu-Mowis; Mounika Mukherjee Peethala; Lisa H Merck; Raffaele Aspide; Katie Dickinson; Guanhong Miao; Guogen Shan; Federico Bilotta; Nicholas A Morris; Giuseppe Citerio; Katharina M Busl
Journal:  Neurocrit Care       Date:  2022-08-02       Impact factor: 3.532

2.  Severe headache trajectory following aneurysmal subarachnoid hemorrhage: the association with lower sodium levels.

Authors:  Robert S Eisinger; Zachary A Sorrentino; Brandon Lucke-Wold; Sonya Zhou; Brooke Barlow; Brian Hoh; Carolina B Maciel; Katharina M Busl
Journal:  Brain Inj       Date:  2022-03-30       Impact factor: 2.167

3.  Pharmaceutical Management for Subarachnoid Hemorrhage.

Authors:  Arnav Barpujari; Chhaya Patel; Rebecca Zelmonovich; Alec Clark; Devan Patel; Kevin Pierre; Kyle Scott; Brandon Lucke Wold
Journal:  Recent Trends Pharm Sci Res       Date:  2021

4.  Pregabalin in the Management of Aneurysmal Subarachnoid Hemorrhage.

Authors:  Sotirios Apostolakis
Journal:  J Neurosci Rural Pract       Date:  2019-10-09

5.  The endogenous neuropeptide calcitonin gene-related peptide after spontaneous subarachnoid hemorrhage-A potential psychoactive prognostic serum biomarker of pain-associated neuropsychological symptoms.

Authors:  Elisabeth Bründl; Martin Proescholdt; Eva-Maria Störr; Petra Schödel; Sylvia Bele; Florian Zeman; Christoph Hohenberger; Martin Kieninger; Nils Ole Schmidt; Karl-Michael Schebesch
Journal:  Front Neurol       Date:  2022-07-28       Impact factor: 4.086

6.  Predictors of Opiate Utilization in the Treatment of Headache and Impact on Three-Month Outcomes Following Subarachnoid Hemorrhage.

Authors:  Dana Klavansky; Sheshali Wanchoo; Amanda Lin; Richard E Temes; Tania Rebeiz
Journal:  Cureus       Date:  2021-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.